Artículo

[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies

Audicio, Paola F.; Castellano, Gustavo EugenioIcon ; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; Riva, Eloisa; Robles, Ana; Cabral, Pablo; Balter, Henia; Oliver, Patricia
Fecha de publicación: 07/2011
Editorial: Pergamon-Elsevier Science Ltd
Revista: Applied Radiation and Isotopes
ISSN: 0969-8043
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:

Resumen

Anti-CD20 (Rituximab®), a specific chimeric monoclonal antibody used in CD20-positive Non-Hodgkin’s Lymphoma, was conjugated to a bifunctional quelate (DOTA) and radiolabeled with 177Lu through a simple method. [177Lu]-DOTA-anti-CD20 was obtained with a radiochemical purity higher than 97%, and showed good chemical and biological stability, maintaining its biospecificity to CD20 antigens. MonteCarlo simulation showed high doses deposited on a spheroid tumor mass model. This method shows to be an appropiate alternative for the production of [177Lu]-DOTA-anti-CD20 as therapeutic radiopharmaceutical.
Palabras clave: CD20 , Non-Hodgkin Lymphoma , 177Lu , Radioimmunotherapy
 
Archivos asociados
Thumbnail
 
Tamaño: 490.9Kb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/271298
URL: https://www.sciencedirect.com/science/article/abs/pii/S0969804311000406
DOI: https://doi.org/10.1016/j.apradiso.2011.01.026
Colecciones
Articulos(IFEG)
Articulos de INST.DE FISICA ENRIQUE GAVIOLA
Citación
Audicio, Paola F.; Castellano, Gustavo Eugenio; Tassano, Marcos R.; Rezzano, Maria E.; Fernandez, Marcelo; et al.; [177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies; Pergamon-Elsevier Science Ltd; Applied Radiation and Isotopes; 69; 7; 7-2011; 924-928
Compartir
Altmétricas